Pristimerin‐induced uveal melanoma cell death via inhibiting PI3K/Akt/FoxO3a signalling pathway
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pristimerin‐induced uveal melanoma cell death via inhibiting PI3K/Akt/FoxO3a signalling pathway
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-04-29
DOI
10.1111/jcmm.15249
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review
- (2019) Jia-jun Li et al. Frontiers in Pharmacology
- Simultaneously Targeting Bcl-2 and Akt Pathways Reverses Resistance of Nasopharyngeal Carcinoma to TRAIL Synergistically
- (2018) Shi-Sheng Li et al. TUMORI
- FOXO Signaling Pathways as Therapeutic Targets in Cancer
- (2017) Mohd Farhan et al. International Journal of Biological Sciences
- Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF-κB pathway
- (2017) Biao Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells
- (2016) Fengxia Yan et al. BIOMEDICINE & PHARMACOTHERAPY
- Pristimerin triggers AIF-dependent programmed necrosis in glioma cells via activation of JNK
- (2016) Hongwei Zhao et al. CANCER LETTERS
- The Pediatric Choroidal and Ciliary Body Melanoma Study
- (2016) Rana'a T. Al-Jamal et al. OPHTHALMOLOGY
- Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2
- (2014) DORRAH DEEB et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Anticancer Activity of Pristimerin in Epidermal Growth Factor Receptor 2-Positive SKBR3 Human Breast Cancer Cells
- (2013) Jin Sun Lee et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer
- (2013) Rhonda L. Bitting et al. CANCER JOURNAL
- Pristimerin Inhibits Breast Cancer Cell Migration by Up-regulating Regulator of G Protein Signaling 4 Expression
- (2012) Xian-Min Mu et al. Asian Pacific Journal of Cancer Prevention
- Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
- (2012) David J. Newman et al. JOURNAL OF NATURAL PRODUCTS
- FoxO3a Negatively Regulates Nerve Growth Factor-Induced Neuronal Differentiation Through Inhibiting the Expression of Neurochondrin in PC12 Cells
- (2012) Haitao Wang et al. MOLECULAR NEUROBIOLOGY
- Pristimerin, a Triterpenoid, Inhibits Tumor Angiogenesis by Targeting VEGFR2 Activation
- (2012) Xianmin Mu et al. MOLECULES
- Pristimerin Causes G1 Arrest, Induces Apoptosis, and Enhances the Chemosensitivity to Gemcitabine in Pancreatic Cancer Cells
- (2012) Yongwei Wang et al. PLoS One
- The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction
- (2012) YAN-YAN YAN et al. Oncology Letters
- Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction
- (2011) Da-Young Eum et al. ANTI-CANCER DRUGS
- FoxO family members in cancer
- (2011) Yuqing Zhang et al. CANCER BIOLOGY & THERAPY
- Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma
- (2011) M. Patel et al. CLINICAL CANCER RESEARCH
- Redox Regulation of the Intrinsic Pathway in Neuronal Apoptosis
- (2010) James L. Franklin ANTIOXIDANTS & REDOX SIGNALING
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
- (2010) Zhongzheng Lu et al. Molecular Cancer
- PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01
- (2010) C. Dudgeon et al. MOLECULAR CANCER THERAPEUTICS
- A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer
- (2009) J.-Y. Yang et al. CLINICAL CANCER RESEARCH
- The PKB/AKT Pathway in Cancer
- (2009) Amancio Carnero CURRENT PHARMACEUTICAL DESIGN
- Pathological Effects of Prostate Cancer Correlate With Neuroendocrine Differentiation and PTEN Expression After Bicalutamide Monotherapy
- (2009) Won Sik Ham et al. JOURNAL OF UROLOGY
- Reactive Oxygen Species-Dependent Activation of Bax and Poly(ADP-ribose) Polymerase-1 Is Required for Mitochondrial Cell Death Induced by Triterpenoid Pristimerin in Human Cervical Cancer Cells
- (2009) J.-Y. Byun et al. MOLECULAR PHARMACOLOGY
- The FoxO code
- (2008) D R Calnan et al. ONCOGENE
- FOXOs, cancer and regulation of apoptosis
- (2008) Z Fu et al. ONCOGENE
- Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells
- (2008) Patricia Marçal da Costa et al. TOXICOLOGY IN VITRO
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search